Ekso Bionics’ (EKSO) “Buy” Rating Reaffirmed at HC Wainwright

Ekso Bionics (NASDAQ:EKSO)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $9.00 price objective on the stock.

Separately, StockNews.com initiated coverage on Ekso Bionics in a report on Monday. They issued a “hold” rating for the company.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $0.48 on Tuesday. The company has a market capitalization of $10.61 million, a price-to-earnings ratio of -0.74 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. Ekso Bionics has a one year low of $0.45 and a one year high of $2.16. The company’s 50-day moving average is $0.61 and its 200 day moving average is $0.83.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The firm had revenue of $5.09 million during the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. Sell-side analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.